# EDGAR Filing Document

**Accession Number:** 0002104204
**File Stem:** 0002126941-26-000004
**Filing Date:** 2026-4
**Character Count:** 11921
**Document Hash:** ee87d10d631a8fb4bf2f632d6c60178b
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0002126941-26-000004.hdr.sgml**: 20260420

**ACCESSION NUMBER**: 0002126941-26-000004

**CONFORMED SUBMISSION TYPE**: 4

**PUBLIC DOCUMENT COUNT**: 1

**CONFORMED PERIOD OF REPORT**: 20260416

**FILED AS OF DATE**: 20260420

**DATE AS OF CHANGE**: 20260420

**REPORTING-OWNER**: 

**OWNER DATA:**
- **COMPANY CONFORMED NAME:** Luo Yuling
- **CENTRAL INDEX KEY:** 0002126941

**ORGANIZATION NAME:**

**FILING VALUES:**
- **FORM TYPE:** 4
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-43235
- **FILM NUMBER:** 26876505

**MAIL ADDRESS:**
- **STREET 1:** 47071 BAYSHORE PARKWAY
- **CITY:** FREMONT
- **STATE:** CA
- **ZIP:** 94538
**ISSUER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Alamar Biosciences, Inc.
- **CENTRAL INDEX KEY:** 0002104204
- **STANDARD INDUSTRIAL CLASSIFICATION:** LABORATORY ANALYTICAL INSTRUMENTS [3826]
- **ORGANIZATION NAME:** 08 Industrial Applications and Services
- **EIN:** 364899036
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**BUSINESS ADDRESS:**
- **STREET 1:** 47071 BAYSIDE PARKWAY
- **CITY:** FREMONT
- **STATE:** CA
- **ZIP:** 94538
- **BUSINESS PHONE:** 510-626-9888

**MAIL ADDRESS:**
- **STREET 1:** 47071 BAYSIDE PARKWAY
- **CITY:** FREMONT
- **STATE:** CA
- **ZIP:** 94538

### UNITED STATES SECURITIES AND EXCHANGE COMMISSION
**Washington, D.C. 20549**

## FORM 4

### STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

[ ] Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

[ ] Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

---

| | | |
|:---|:---|:---|
| **1. Name and Address of Reporting Person**<sup>*</sup><br>Luo Yuling<br><sub>(Last) (First) (Middle)</sub><br>C/O ALAMAR BIOSCIENCES, INC.<br>47071 BAYSIDE PARKWAY<br><sub>(Street)</sub><br>FREMONT, CA 94538<br><sub>(City) (State) (Zip)</sub> | **3. Date of Earliest Transaction (Month/Day/Year)**<br>2026-04-16 | **5. Relationship of Reporting Person(s) to Issuer**<br>(Check all applicable)<br>[X] Director [ ] 10% Owner<br>[X] Officer (give title below) [ ] Other (specify below)<br>_Chief Executive Officer_ |
| **2. Issuer Name and Ticker or Trading Symbol**<br>Alamar Biosciences, Inc. [ ALMR ] | **4. If Amendment, Date of Original Filed (Month/Day/Year)**<br>  | **6. Individual or Joint/Group Filing (Check Applicable Line)**<br>[X] Form filed by One Reporting Person<br>[ ] Form filed by More than One Reporting Person |

---

## Table I - Non-Derivative Securities

---

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| 1. Title of Security | 2. Transaction Date | 2A. Deemed Execution Date | 3. Transaction Code (V) | 3. Transaction Code (V) | 4. Securities Acquired (A) or Disposed of (D) | 4. Securities Acquired (A) or Disposed of (D) | 4. Securities Acquired (A) or Disposed of (D) | 5. Amount of Securities Beneficially Owned | 6. Ownership Form | 7. Nature of Indirect Beneficial Ownership |
| 1. Title of Security | 2. Transaction Date | 2A. Deemed Execution Date | Code | V | Amount | (A) or (D) | Price | 5. Amount of Securities Beneficially Owned | 6. Ownership Form | 7. Nature of Indirect Beneficial Ownership |
| Class B Common Stock | 2026-04-20 |  | C<sup>(1)</sup> |  | 1386746 | A | <sup>(1)</sup> | 1499797 | D |  |
| Class B Common Stock | 2026-04-20 |  | C<sup>(2)</sup> |  | 364268 | A | <sup>(2)</sup> | 1864065 | D |  |
| Class B Common Stock | 2026-04-20 |  | J<sup>(3)</sup> |  | 1864065 | D | <sup>(3)</sup> | 0 | D |  |
| Common Stock | 2026-04-20 |  | J<sup>(3)</sup> |  | 1864065 | A | <sup>(3)</sup> | 1864065 | D |  |
| Common Stock | 2026-04-20 |  | A<sup>(4)</sup> |  | 76509 | A | $0 | 1940574 | D |  |
| Class B Common Stock | 2026-04-20 |  | C<sup>(1)</sup> |  | 1224152 | A | <sup>(1)</sup> | 1224152 | I | By Spouse |
| Class B Common Stock | 2026-04-20 |  | J<sup>(3)</sup> |  | 1224152 | D | <sup>(3)</sup> | 0 | I | By Spouse |
| Common Stock | 2026-04-20 |  | J<sup>(3)</sup> |  | 1224152 | A | <sup>(3)</sup> | 1224152 | I | By Spouse |

---

## Table II - Derivative Securities

---

|  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| 1. Title of Derivative Security | 2. Conversion or Exercise Price | 3. Transaction Date | 3A. Deemed Execution Date | 4. Transaction Code (V) | 4. Transaction Code (V) | 5. Number of Derivative Securities Acquired (A) or Disposed of (D) | 5. Number of Derivative Securities Acquired (A) or Disposed of (D) | 6. Date Exercisable and Expiration Date | 6. Date Exercisable and Expiration Date | 7. Title and Amount of Underlying Securities | 7. Title and Amount of Underlying Securities | 8. Price of Derivative Security | 9. Number of Derivative Securities Beneficially Owned | 10. Ownership Form | 11. Nature of Indirect Beneficial Ownership |
| 1. Title of Derivative Security | 2. Conversion or Exercise Price | 3. Transaction Date | 3A. Deemed Execution Date | Code | V | (A) | (D) | Date Exercisable | Expiration Date | Title | Amount or Number of Shares | 8. Price of Derivative Security | 9. Number of Derivative Securities Beneficially Owned | 10. Ownership Form | 11. Nature of Indirect Beneficial Ownership |
| Stock Option (Right to Buy) | $17 | 2026-04-16 |  | A |  | 341191 |  | <sup>(5)</sup> | 2036-04-15 | Common Stock | 341191 | $0 | 341191 | D |  |
| Class A Common Stock | <sup>(1)</sup> | 2026-04-20 |  | C |  |  | 1020742 | <sup>(1)</sup> | <sup>(1)</sup> | Class B Common Stock | 1020742 | $0 | 0 | D |  |
| Founders Preferred Stock | <sup>(1)</sup> | 2026-04-20 |  | C |  |  | 366004 | <sup>(1)</sup> | <sup>(1)</sup> | Class B Common Stock | 366004 | $0 | 0 | D |  |
| Series A-1 Preferred Stock | <sup>(2)</sup> | 2026-04-20 |  | C |  |  | 880802 | <sup>(2)</sup> | <sup>(2)</sup> | Class B Common Stock | 364268 | $0 | 0 | D |  |
| Class A Common Stock | <sup>(1)</sup> | 2026-04-20 |  | C |  |  | 1224152 | <sup>(1)</sup> | <sup>(1)</sup> | Class B Common Stock | 1224152 | $0 | 0 | I | By Spouse |
| Stock Option (Right to Buy) | $2.51 | 2026-04-20 |  | J<sup>(3)</sup> |  |  | 266311 | <sup>(6)</sup> | 2027-02-15 | Class B Common Stock | 266311 | $0 | 0 | D |  |
| Stock Option (Right to Buy) | $2.51 | 2026-04-20 |  | J<sup>(3)</sup> |  | 266311 |  | <sup>(6)</sup> | 2027-02-15 | Common Stock | 266311 | $0 | 266311 | D |  |
| Stock Option (Right to Buy) | $2.51 | 2026-04-20 |  | J<sup>(3)</sup> |  |  | 25310 | <sup>(6)</sup> | 2027-02-15 | Class B Common Stock | 25310 | $0 | 0 | D |  |
| Stock Option (Right to Buy) | $2.51 | 2026-04-20 |  | J<sup>(3)</sup> |  | 25310 |  | <sup>(6)</sup> | 2027-02-15 | Common Stock | 25310 | $0 | 25310 | D |  |
| Stock Option (Right to Buy) | $1.53 | 2026-04-20 |  | J<sup>(3)</sup> |  |  | 23986 | <sup>(7)</sup> | 2033-01-17 | Class B Common Stock | 23986 | $0 | 0 | D |  |
| Stock Option (Right to Buy) | $1.53 | 2026-04-20 |  | J<sup>(3)</sup> |  | 23986 |  | <sup>(7)</sup> | 2033-01-17 | Common Stock | 23986 | $0 | 23986 | D |  |
| Stock Option (Right to Buy) | $1.53 | 2026-04-20 |  | J<sup>(3)</sup> |  |  | 20023 | <sup>(6)</sup> | 2033-04-24 | Class B Common Stock | 20023 | $0 | 0 | D |  |
| Stock Option (Right to Buy) | $1.53 | 2026-04-20 |  | J<sup>(3)</sup> |  | 20023 |  | <sup>(6)</sup> | 2033-04-24 | Common Stock | 20023 | $0 | 20023 | D |  |
| Stock Option (Right to Buy) | $3.34 | 2026-04-20 |  | J<sup>(3)</sup> |  |  | 27700 | <sup>(8)</sup> | 2034-04-16 | Class B Common Stock | 27700 | $0 | 0 | D |  |
| Stock Option (Right to Buy) | $3.34 | 2026-04-20 |  | J<sup>(3)</sup> |  | 27700 |  | <sup>(8)</sup> | 2034-04-16 | Common Stock | 27700 | $0 | 27700 | D |  |
| Stock Option (Right to Buy) | $3.34 | 2026-04-20 |  | J<sup>(3)</sup> |  |  | 1033912 | <sup>(9)</sup> | 2035-01-15 | Class B Common Stock | 1033912 | $0 | 0 | D |  |
| Stock Option (Right to Buy) | $3.34 | 2026-04-20 |  | J<sup>(3)</sup> |  | 1033912 |  | <sup>(9)</sup> | 2035-01-15 | Common Stock | 1033912 | $0 | 1033912 | D |  |
| Stock Option (Right to Buy) | $3.34 | 2026-04-20 |  | J<sup>(3)</sup> |  |  | 37086 | <sup>(10)</sup> | 2035-01-15 | Class B Common Stock | 37086 | $0 | 0 | D |  |
| Stock Option (Right to Buy) | $3.34 | 2026-04-20 |  | J<sup>(3)</sup> |  | 37086 |  | <sup>(10)</sup> | 2035-01-15 | Common Stock | 37086 | $0 | 37086 | D |  |
| Stock Option (Right to Buy) | $7.60 | 2026-04-20 |  | J<sup>(3)</sup> |  |  | 42334 | <sup>(11)</sup> | 2036-01-14 | Class B Common Stock | 42334 | $0 | 0 | D |  |
| Stock Option ((Right to Buy) | $7.60 | 2026-04-20 |  | J<sup>(3)</sup> |  | 42334 |  | <sup>(11)</sup> | 2036-01-14 | Common Stock | 42334 | $0 | 42334 | D |  |

---

### Footnotes:

(1) The Class A Common Stock and Founders Preferred Stock are convertible into shares of Class B Common Stock on a 1:1 basis and have no expiration date. The Class A Common Stock and Founders Preferred Stock automatically converted into shares of Class B Common Stock immediately prior to the completion of the initial public offering of the Issuer's Common Stock (the "IPO").

(2) The Series A-1 Preferred Stock is convertible into shares of Class B Common Stock on a 1:2.418 basis and has no expiration date. The Series A-1 Preferred Stock automatically converted into shares of Class B Common Stock immediately prior to the completion of the IPO.

(3) Each share of Class B Common Stock was reclassified into one share of Common Stock immediately prior to the completion of the IPO.

(4) Represents the grant of restricted stock units ("RSUs"). The RSUs vest monthly from the date of grant, subject to the reporting person's continuous service as of each such vesting date.

(5) Twenty-five percent of the shares subject to the option vest on April 16, 2027, and 1/48th of the shares vest monthly thereafter, subject to the reporting person's continuous service as of each such vesting date.

(6) Fully vested.

(7) The shares subject to the option vest in equal monthly installments over 48 months measured from January 1, 2023, subject to the reporting person's continuous service as of each such vesting date.

(8) The shares subject to the option vest in equal monthly installments over 48 months measured from January 1, 2024, subject to the reporting person's continuous service as of each such vesting date.

(9) The shares subject to the option vest in equal monthly installments over 48 months measured from January 16, 2025, subject to the reporting person's continuous service as of each such vesting date.

(10) The shares subject to the option vest in equal monthly installments over 48 months measured from January 1, 2025, subject to the reporting person's continuous service as of each such vesting date.

(11) The shares subject to the option vest in equal monthly installments over 48 months measured from January 1, 2026, subject to the reporting person's continuous service as of each such vesting date.

**Signature:** /s/ Timothy White, Attorney-in-Fact  
**Date:** 2026-04-20

### Remarks:

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

**Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.**